首页> 中文期刊> 《中国继续医学教育》 >沙美特罗替卡松气雾剂与孟鲁司特钠联合治疗支气管哮喘63例临床效果分析

沙美特罗替卡松气雾剂与孟鲁司特钠联合治疗支气管哮喘63例临床效果分析

         

摘要

目的:分析舒利迭与孟鲁司特钠联合治疗支气管哮喘的临床效果。方法将125例支气管哮喘患者分为2组,实验组63例给予舒利迭与孟鲁司特钠联合治疗,对照组62例给予单纯孟鲁司特钠治疗。结果研究组总有效率(96.83%)高于对照组(70.97%),其治疗后FEV1[(90.13±15.84)%]、FVC[(95.23±12.67)%]、PEF[(81.10±8.74)%]高于对照组[FEV1:(80.11±13.61)%、FVC:(81.16±15.97)%、PEF:(64.49±9.37)%],两组差异有统计学意义(P<0.05)。结论舒利迭与孟鲁司特钠联合治疗支气管哮喘,临床疗效显著,FEV1、FVC、PEF改善明显。%Objective To analyze the clinical effects of seretide and montelukast sodium combined with treatment of bronchial asthma. Methods125 cases of bronchial asthma were divided into 2 groups, 63 cases in experimental group were given seretide and montelukast sodium combined therapy, 62 cases in the control group treated with montelukast sodium in the treatment of.ResultsThe study group total effective rate (96.83%) was signiifcantly higher than the control group (70.97%), after the treatment of early FEV1[(90.13± 15.84), FVC[(95.23± 12.67) of early, PEF[(81.10± 8.74) of early than that in the control group [FEV1: (80.11 ± 13.61)%, FVC: (81.16± 15.97)%, PEF: (64.49± 9.37) of early, with a signiifcant difference between two groups (P<0.05).Conclusion Seretide and montelukast sodium combined with treatment of bronchial asthma, clinical curative effect, FEV1, FVC, PEF improved signiifcantly.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号